SCHEMBL1163552

SCHEMBL1163552

Cc1ccc(CN)c(N(C)S(C)(=O)=O)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 3/20 0.40
HTT P42858 1/20 0.40
AKR1B1 P15121 1/20 0.38
ALDH1A1 P00352 2/20 0.38
CYP19A1 P11511 2/20 0.38
NPSR1 Q6W5P4 1/20 0.36
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
C5AR1 P21730 1/20 0.34
TAAR1 Q96RJ0 1/20 0.33
LMNA P02545 1/20 0.33
KDM4E B2RXH2 1/20 0.33
PKM P14618 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL1627022 0.93 PTK2 (0.40) PTK2HTTAKR1B1ALDH1A1CYP19A1
SCHEMBL12409789 0.87 CYP19A1 (0.40) PTK2HTTAKR1B1ALDH1A1CYP19A1
SCHEMBL26511945 0.86 PTK2 (0.42) PTK2HTTAKR1B1ALDH1A1CYP19A1
Hydrochloric Acid SCHEMBL17258854 0.85 PTK2 (0.40) PTK2HTTAKR1B1ALDH1A1CYP19A1
Hydrochloric Acid SCHEMBL21048926 0.78 CYP19A1 (0.41) ALDH1A1CYP19A1KMT2ATAAR1LMNA
SCHEMBL31484766 0.78 TAAR1 (0.39) ALDH1A1TAAR1SLC6A2SLC6A4SLC6A3
SCHEMBL30621311 0.77 KMT2A (0.46) PTK2ALDH1A1CYP19A1NPSR1KMT2A
SCHEMBL1291311 0.77 KMT2A (0.46) PTK2ALDH1A1CYP19A1NPSR1KMT2A
SCHEMBL29686578 0.77 TDP1 (0.43) HTTAKR1B1ALDH1A1CYP19A1NPSR1
SCHEMBL20073375 0.77 TDP1 (0.43) HTTAKR1B1ALDH1A1CYP19A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10450297-B2 Sulfonyl amide derivatives for the treatment of abnormal cell growth PFIZER, INC. (US) 2019-10-22 US disclosed
US-20190047979-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2019-02-14 US disclosed
US-20170327485-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2017-11-16 US disclosed
US-20170327485-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2017-11-16 US disclosed
US-20170001981-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2017-01-05 US disclosed
US-20170001981-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2017-01-05 US disclosed
EP-2464634-B1 REGIOSELECTIVE PREPARATION OF 2-AMINO-5-TRIFLUOROMETHYLPYRIMIDINE DERIVATIVES BOEHRINGER INGELHEIM INT (DE) 2016-11-30 EP disclosed
EP-2146779-B1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PROD INC (US) 2016-08-10 EP disclosed
US-20160130250-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2016-05-12 US disclosed
US-20160130250-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2016-05-12 US disclosed
US-20110275633-A1 2,4-DIAMINOPYRIMIDINE DERIVATES AS PTK2- INHIBITORS FOR THE TREATMENT OF ABNORMAL CELL GROWTH BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-10 US disclosed
US-20110190499-A1 SELECTIVE SYNTHESIS OF FUNCTIONALIZED PYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-08-04 US disclosed
US-20110166120-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2011-07-07 US disclosed
US-7928109-B2 focal adhesion kinase inhibitor, i.e. FAK inhibitor; tyrosine kinase inhibitors; cancer, osteoporosis; e.g. N-methyl-4-({4-[({3-[methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride PFIZER INC (US) 2011-04-19 US disclosed
US-7928109-B2 focal adhesion kinase inhibitor, i.e. FAK inhibitor; tyrosine kinase inhibitors; cancer, osteoporosis; e.g. N-methyl-4-({4-[({3-[methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride PFIZER INC (US) 2011-04-19 US disclosed
WO-2011018517-A1 REGIOSELECTIVE PREPARATION OF 2-AMINO-5-TRIFLUOROMETHYLPYRIMIDINE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-02-17 WO disclosed
WO-2011018518-A1 REGIOSELECTIVE PREPARATION OF 2 -AMINO-5-TRIFLUOROMETHYLPYRIMIDINE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-02-17 WO disclosed
WO-2010055117-A1 2,4-DIAMINOPYRIMIDINE DERIVATES AS PTK2- INHIBITORS FOR THE TREATMENT OF ABNORMAL CELL GROWTH BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-05-20 WO disclosed
US-20090054395-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2009-02-26 US disclosed
US-20090054395-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190499-A1 SELECTIVE SYNTHESIS OF FUNCTIONALIZED PYRIMIDINES DPYD, TYMS, UMPS PTK2 3914/4885HTT 3210/4885AKR1B1 1391/4885
US-10450297-B2 Sulfonyl amide derivatives for the treatment of abnormal cell growth GPR119, INSR, LYAR PTK2 4052/4885HTT 1714/4885AKR1B1 418/4885
US-20170001981-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885HTT 1714/4885AKR1B1 418/4885
US-20110166120-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885HTT 1714/4885AKR1B1 418/4885
US-20170327485-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885HTT 1714/4885AKR1B1 418/4885
US-20190047979-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885HTT 1714/4885AKR1B1 418/4885
US-20110275633-A1 2,4-DIAMINOPYRIMIDINE DERIVATES AS PTK2- INHIBITORS FOR THE TREATMENT OF ABNORMAL CELL GROWTH PTK2B, CDK2, PTK2 PTK2 3/4885HTT 3692/4885AKR1B1 1492/4885
US-20090054395-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885HTT 1714/4885AKR1B1 418/4885
US-20160130250-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR PTK2 4052/4885HTT 1714/4885AKR1B1 418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.